# EQ catalysts: Equillium, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eq/catalysts

> Equillium, Inc. (EQ) has 1 upcoming catalyst. The next is the EQ504 topline data readout, Q2 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for EQ?

Equillium, Inc. (EQ) has 1 upcoming catalyst. The next is the EQ504 topline data readout, Q2 2027. Press release filed with the SEC (EX-99): "Equillium expects to report topline data, including proof-of-mechanism assessments, in the second quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/eq/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-458379, https://www.sec.gov/Archives/edgar/data/1746466/000119312526458379/eq-ex99_1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/eq/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Equillium, Inc. |
| Ticker | EQ (Nasdaq) |
| SEC CIK | 1746466 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eq |

## Cash runway

Cash $53.3M as of 2026-09-30; quarterly burn $3.8M; about 41.8 months of runway at that rate (XBRL company facts, accession 0001193125-26-458443).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [Itolizumab trial start](https://sec-api.dev/pdufa/itolizumab) | EQ | moderate to severe alopecia areata, or AA, in Australia and New Zealand | completed | "In November 2022, we initiated a Phase 2 proof-of-concept clinical study of EQ101 administered intravenously, or IV, in subjects with moderate to severe alopecia areata, or AA, in Australia and New Zealand." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm)) |
| Apr 2024 | [Itolizumab topline data readout](https://sec-api.dev/pdufa/itolizumab) | EQ |  | completed, positive | "In April 2024, we announced positive topline data from the Type B LN portion of that study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm)) |
| Jun 2024 | [Itolizumab topline data readout](https://sec-api.dev/pdufa/itolizumab) | EQ | alopecia areata, or AA, and in June 2024, we | completed, positive | "We completed a Phase 2 proof-of-concept clinical study of EQ101 in subjects with alopecia areata, or AA, and in June 2024, we announced positive topline data from that study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm)) |
| November 13, 2024 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-ex99_1.htm)) |
| Q1 2025 | [Itolizumab topline data readout](https://sec-api.dev/pdufa/itolizumab) | EQ |  | scheduled | "In addition, in collaboration with Equillium, our partner Biocon has recently completed a robust placebo-controlled Phase 2 study of itolizumab in biologic-na&iuml;ve patients with moderate to severe ulcerative colitis, and we expect topline data from this study also in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-ex99_1.htm)) |
| Feb 2025 | [Itolizumab topline data readout](https://sec-api.dev/pdufa/itolizumab) | EQ |  | completed, positive | "In February 2025, we announced positive topline data from the study in which itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm)) |
| Mar 2025 | [Itolizumab topline data readout](https://sec-api.dev/pdufa/itolizumab) | EQ | acute graft-versus-host disease, or aGVHD, where itolizumab | completed, mixed | "In March 2025, we announced topline results from our Phase 3 EQUATOR study of itolizumab (EQ001) in patients with acute graft-versus-host disease, or aGVHD, where itolizumab (EQ001) did not meet the Day 29 outcomes of complete response, or CR, a primary outcome, and overall response rate, or ORR, a key secondary outcome, but there was a clinically meaningful improvement in durable CR from Day 29 to 99, a key secondary outcome, and statistically significant evidence of clinical benefit was also observed on pre-specified secondary endpoints of duration of CR and failure free survival." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000095017025108834/eq-20250630.htm)) |
| March 27, 2025 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/eq-ex99_1.htm)) |
| August 3, 2025 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "the risk that the reported financial results will differ from the estimates provided in this press release" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312525172207/d113174dex991.htm)) |
| November 13, 2025 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312525280173/eq-ex99_1.htm)) |
| Q1 2026 | [EQ504 trial start](https://sec-api.dev/pdufa/eq504) | EQ |  | scheduled | "We are currently focused on raising additional capital to advance the preclinical development of EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, and subject to raising additional capital during the second quarter of 2025, expect to be ready to initiate a first-in-human Phase 1 clinical study in the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000095017025071389/eq-20250331.htm)) |
| March 25, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124107/eq-ex99_1.htm)) |
| May 13, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/eq-ex99_1.htm)) |
| August 13, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-ex99_1.htm)) |
| Q4 2026 | [EQ504 trial start](https://sec-api.dev/pdufa/eq504) | EQ |  | scheduled | "We intend to initiate a Phase 1 placebo-controlled proof-of-mechanism study for EQ504, a novel AhR modulator, in the fourth quarter of 2026, with data expected approximately six months thereafter; provided, however, we cannot provide any assurances that we will be able to obtain data within those time frames or that the data which may be obtained will be favorable to the further clinical development of EQ504." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349235/eq-20260630.htm)) |
| Q4 2026 | [EQ504 topline data readout](https://sec-api.dev/pdufa/eq504) | EQ |  | scheduled | "Advancing EQ504 toward the clinic, with the Phase 1 proof-of-mechanism study expected to initiate in the fourth quarter of 2026, and topline data anticipated approximately six months thereafter." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-ex99_1.htm)) |
| October 26, 2026 | [EQ504 trial start](https://sec-api.dev/pdufa/eq504) | EQ |  | completed | "On October 26, 2026, concurrent with the first patient dosed in the Phase 1 clinical trial, Equillium closed the second tranche of the Company's previously announced August 2025 equity private placement agreement, resulting in aggregate gross proceeds of approximately $20 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526458379/eq-ex99_1.htm)) |
| November 12, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526458379/eq-ex99_1.htm)) |
| Q2 2027 | [EQ504 topline data readout](https://sec-api.dev/pdufa/eq504) | EQ |  | scheduled | "Equillium expects to report topline data, including proof-of-mechanism assessments, in the second quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526458379/eq-ex99_1.htm)) |

## Drugs

- [EQ504](https://sec-api.dev/pdufa/eq504): 
- [Itolizumab](https://sec-api.dev/pdufa/itolizumab): acute graft-versus-host disease, or agvhd, where itolizumab, alopecia areata, or aa, and in june 2024, we, alopecia areata, or aa, in australia and new zealand, and in june 2024, we, moderate to severe alopecia areata, or aa, in australia and new zealand

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eq/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EQ catalysts: Equillium, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eq/catalysts

```bibtex
@misc{secapidev_companies_eq_catalysts_20261116,
  title        = {EQ catalysts: Equillium, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eq/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eq_catalysts_20261116","title":"EQ catalysts: Equillium, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eq/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
